Genta Returns To Old Territory With New Genasense Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Genasense/chemotherapy combination will be tried in approximately 300 biomarker-targeted treatment naive melanoma patients.
You may also be interested in...
Time To Call It Quits: Genasense Failure Marks Its End And Leaves Genta On The Ropes Again
Genta ended a decade-long effort to validate the effectiveness of Genasense (oblimersen) with the May 23 announcement that the troubled antisense asset performed little better than chemotherapy alone in a targeted subset of patients with advanced melanoma.
Time To Call It Quits: Genasense Failure Marks Its End And Leaves Genta On The Ropes Again
Genta ended a decade-long effort to validate the effectiveness of Genasense (oblimersen) with the May 23 announcement that the troubled antisense asset performed little better than chemotherapy alone in a targeted subset of patients with advanced melanoma.
Genasense Phase III Melanoma Trial Gets Green Light
Genta aims for first approval in tough disease, CEO tells “The Pink Sheet” DAILY.